ENGN (enGene Therapeutics) Institutional Ownership: 85.66% (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENGN enGene Therapeutics Inc ENGN
12 GF Score
Price $1.72
! 1 Warning Sign
View Full Analysis

What is enGene Therapeutics Institutional Ownership?

enGene Therapeutics ENGN +1.78% 12 Institutional Ownership is 85.66% as of Aug. 18, 2026. GuruFocus rates ENGN with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, enGene Therapeutics's institutional ownership is 85.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, enGene Therapeutics's Insider Ownership is 4.79%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, enGene Therapeutics's Float Percentage Of Total Shares Outstanding is 81.17%.

enGene Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for enGene Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

enGene Therapeutics Institutional Ownership Chart

enGene Therapeutics Historical Data

The historical data trend for enGene Therapeutics can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 3.54 3.77 5.38 5.59 5.77 4.94 4.96 0.89 0.48 0.48
ENGN
12GF Score
enGene Therapeutics Inc ENGN
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

enGene Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 85.66% mean?
enGene Therapeutics (ENGN) has a Institutional Ownership of 85.66% as of Aug. 18, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on enGene Therapeutics and its competitors.
Is enGene Therapeutics' Institutional Ownership too high?
enGene Therapeutics' current Institutional Ownership is 85.66%. Overall, enGene Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' Institutional Ownership compare to VTVT and GUTS?
enGene Therapeutics' Institutional Ownership of 85.66% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on enGene Therapeutics and its competitors. enGene Therapeutics's current Institutional Ownership is 85.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (ENGN) has a current Institutional Ownership of 85.66%. The current Institutional Ownership is 85.66%. enGene Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For enGene Therapeutics (ENGN), the current Institutional Ownership is 85.66% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

enGene Therapeutics Business Description

Other Exchanges S0N0:Germany
Address 4868 Rue Levy, Suite 220, Saint-Laurent, QC, CAN, H4R 2P1
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
12GF Score

Get the complete analysis for ENGN

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price